As much as TAVR's popularity has grown in recent years, there are still many instances when a heart team may find that surgery offers the best path forward. 

Researchers examined data from more than 700 TAVR patients, publishing their findings in the American Journal of Cardiology.

Catch up on the biggest news that came out of the second day of ACC.23 in New Orleans. 

The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward. 

ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

Both vendors used the four-day conference as an opportunity to provide key updates about their TAVR valves.

Early SVD has been reported in these devices, particularly three to four years after implantation. According to the FDA, this has resulted in surgical replacement procedures and transcatheter valve-in-valve interventions. In some cases, the patient died.

The device, which gained FDA approval in 2021, was part of a voluntary recall in 2022 due to stability concerns. Medtronic worked with the FDA to address the issue, and the Harmony TPV is once again available throughout the United States. 

The 3D-printed models are soft, flexible and can mimic the way a patient's heart may respond to different interventions. 

According to new research published in the American Journal of Cardiology, complex CAD appears to affect long-term TAVR outcomes much more for women than it does for men.   

TEE has been used to guide most transcatheter structural heart cases over the past decade, but 3D ICE is changing how some centers image those patients. 

Morristown Medical Center first started performing TAVR procedures in 2011 and is now home to one of the largest TAVR programs in the United States.